BackTakeda Pharmaceutical Company Limited Overview

Takeda Pharmaceutical Company Limited Receivables

Track Takeda Pharmaceutical Company Limited's receivables ($910B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$910.25B
↑ 29.62% YoYΔ $208.01B vs prior year quarter

Peer trimmed avg / median

Loading

Takeda Pharmaceutical Company Limited Receivables History

Loading

Takeda Pharmaceutical Company Limited vs. peers: Receivables Comparison

Loading

Takeda Pharmaceutical Company Limited Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Takeda Pharmaceutical Company Limited (TKPHF) FAQ

Takeda Pharmaceutical Company Limited posts a receivables of $910B as of September 2026. That compares with $700B in the prior-year period — up 29.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Takeda Pharmaceutical Company Limited's receivables was $700B. The latest reading is $910B — a 29.6% year-over-year increase (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Takeda Pharmaceutical Company Limited's financial statement story. At $910B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TKPHF's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Takeda Pharmaceutical Company Limited's other metric pages and overview cover the third.

Judging Takeda Pharmaceutical Company Limited against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $910B here, then scan peer and history charts to see if the gap is persistent.